Treatment for Older Prostate Cancer Patients
Disparities in a Southern State
Datos Bibliográficos
| ID | 9102930 |
|---|---|
| Autores | Maria Pisu (University of Alabama at Birmingham, autor de correspondencia), Joann S Oliver (0000-0002-5623-6480, University of Alabama), Young-Il Kim (0000-0001-6806-4551), Young‐Il Kim (0000-0002-0145-7382, University of Alabama at Birmingham, autor de correspondencia), Keith Elder (0000-0002-4932-0852, University of Alabama at Birmingham), Michelle Martin, Michelle D Martin (0009-0003-8001-6714, University of Alabama at Birmingham, autor de correspondencia), Lisa C Richardson (0000-0002-9555-7674) |
| Año | 2010 |
| Volumen | 48 |
| Número | 10 |
| Páginas | 915-922 |
| Fecha de publicación | 2010-10-01 |
| Peer Reviewed | Sí |
| Open Access | No |
| Tipo | ARTICLE |
| Revista | Medical Care (JOURNAL) |
| Identificadores de la revista | ISSN: 0025-7079 • E-ISSN: 1537-1948 |
| Editorial | Ovid Technologies (Wolters Kluwer Health) (PUBLISHER) |
| DOI | 10.1097/mlr.0b013e3181eb31a8 |
| PMID | 20733530 |
| OpenAlex | W2027670722 |
| Idioma | EN |
| Referencias citadas | 29 |
BACKGROUND: Black prostate cancer patients are less likely to receive aggressive therapy (AT) than Whites: reported rates for patients ≥ 65 years old are about 55% versus 65%. Little is known about treatment rates in socioeconomically deprived states with large Black populations like Alabama. STUDY DESIGN: Medicare claims and Alabama Statewide Cancer Registry records were linked for Alabamian men in Medicare fee-for-service diagnosed with loco-regional prostate cancer in 2000-2002. The association between race and likelihood of: (1) AT (prostatectomy or external beam radiation therapy [EBRT] or brachytherapy); (2) hormone therapy (primary androgen deprivation therapy [ADT] or orchiectomy); (3) <30 days of EBRT; and (4) <6 months of ADT, was investigated adjusting for age, clinical tumor stage, grade, Comorbidity Index, and census tract proportion of Black residents, of persons living below poverty and with ≤ high school. RESULTS: Of 3561 patients, 71.2% received AT and 38.3% hormone therapy. Blacks were less likely to receive AT (64.3% vs. 73.0%, adjusted [adj.] OR: 0.80, CI: 0.67-0.96). There was no difference between Blacks and Whites in the likelihood of receiving hormone therapy (40.8% vs. 37.7%, adj. OR: 1.10, CI: 0.91-1.34), <30 days of EBRT (30.5% vs. 31.5%, adj. OR: 0.98, CI: 0.72-1.32) or <6 months of ADT (50.7% vs. 54.0%, adj. OR: 0.84, CI: 0.63-1.12). CONCLUSIONS: In Alabama, there were racial differences in utilization of aggressive treatment for locoregional prostate cancer. Research should investigate factors associated with prostate cancer treatment among older men, such as patient behavior and access to care
Androgen deprivation therapy · Brachytherapy · Breast cancer · Cancer · Cancer registry · Comorbidity · Gynecology · Hormone therapy · Prostate cancer · Prostatectomy · Radiation therapy · Cancer survivorship and care · Internal Medicine · Medicine · Oncology · Prostate Cancer Diagnosis and Treatment · Prostate Cancer Treatment and Research
Development of a comorbidity index using physician claims data
Racial and Ethnic Disparities in the Receipt of Cancer Treatment
Who You Are and Where You Live
Predictors of Aggressive Therapy for Nonmetastatic Prostate Carcinoma in Massachusetts From 1998 to 2002
The Influence of Patient Race and Social Vulnerability on Urologist Treatment Recommendations in Localized Prostate Carcinoma
| Velocidad de citación | historical |
|---|---|
| Altamente citado | No |